“At a time when most Americans are demanding long overdue changes in federal cannabis policy, Acting DEA Administrator Derek Maltz epitomizes the failed policies and approaches of the past.”
Tag: scheduling
DEA Administrative Law Judge John Mulrooney has ordered witness testimony to begin on Tuesday, January 21, 2025.
Nearly 40 years ago, advocates made the case to the DEA’s own judge that cannabis did not meet the definition of a Schedule I controlled substance. Their case is exponentially stronger now.
The hearing is scheduled to commence on Monday, December 2, 2024.
Federal health officials concluded, “The risks to the public health posed by marijuana are low compared to other drugs of abuse,” such as benzodiazepines — a Schedule IV drug, or alcohol, which is unscheduled.
The House Judiciary Committee has posted a markup for HR 3884, the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act on Wednesday, November 20th and they will likely hold a vote on the same day.
While it remains unknown at present time if the DEA will respond favorably to this current rescheduling effort, it has become apparent in recent years that reclassifying cannabis from schedule I to schedule II – the same category as cocaine – falls well short of the sort of federal reform necessary to reflect America’s emerging reefer reality.
Fifty-two percent of registered voters support legalizing marijuana “for recreational use,” according to national tracking poll data compiled by Morning Consult — a Washington DC consulting firm.